drugset / Trial / NCT06006923
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
RandomizedSequentialOpen-labelTreatment
Summary
This is a trial of Regorafenib in combination with pembrolizumab for patients with MSI-H colorectal cancer consisting of lead-in phase examining preliminary efficacy and safety, followed by a randomized phase to further examine efficacy.
Timeline
- Start
- 2024-06-26
- Primary completion
- 2025-07-11
- Completion
- 2025-11-12
Outcome
Outcome not reported
Stopped (Business): “Terminated per directive from Bayer due to funding.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Subject | Regorafenib | Small molecule | 90 mg | — |